Basic and clinical studies on temafloxacin in urology

概要

論文の詳細を見る
We studied temafloxacin (TMFX), a new oral antimicrobial agent, for its absorption and excretion, clinical efficacy and side effects.<BR>1) TMFX 200mg and norfloxacin (NFLX) 200mg were administered to five healthy volunteers. Serum levels reached a maximum of 1.37± 0.13μg/ml at 2 h with TMFX and 0.71±0.38μg/ml at 2 h with NFLX. The urinary recovery rates within 24 h were 65.5±7.8% with TMFX and 42.7±11.3% with NFLX.<BR>2) Twenty-eight patients with genitourinary tract infections were treated with TMFX. They consisted of 11 patients with acute uncomplicated cystitis (AUC), 10 with complicated urinary tract infection (CUTI), 3 with non-gonococcal urethritis (NGU), 3 with chronic prostatitis and one with acute epididymitis. Eight patients with AUC, 3 of 8 with CUTI and 2 with NGU were effectively treated by the criteria of the Japanese UTI Committee.<BR>3) No side effects were observed. Clinical laboratory tests showed no abnormalities in any of the 28 cases.
公益社団法人日本化学療法学会の論文